Robert Knight
- Hematology top 0.02%
- Multiple Myeloma Research and Treatments 109
- Acute Myeloid Leukemia Research 37
- Oncology top 0.2%
- Cancer Treatment and Pharmacology 51
- Bone health and treatments 13
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 22
- Molecular Biology top 0.5%
- Protein Degradation and Inhibitors 45
- Developmental Biology and Gene Regulation 16
- Cancer therapeutics and mechanisms 14
- Co-authors
- Jerome B. ZeldisZhinuan YuMarta OlesnyckyjMeletios Α. DimopoulosJohn J. SeamanDirk J. ReitsmaJoseph F. SimeoneJohn Patin
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United StatesUnited KingdomGreece
In The Last Decade
Robert Knight
201 papers receiving 12.2k citations
Hit Papers
Peers
Comparison fields: 5 of 148
- Hematology 7.9k
- Oncology 6.5k
- Genetics 1.9k
- Orthopedics and Sports Medicine 793
- Molecular Biology 6.2k
Countries citing papers authored by Robert Knight
This map shows the geographic impact of Robert Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Knight more than expected).
Fields of papers citing papers by Robert Knight
This network shows the impact of papers produced by Robert Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Knight. The network helps show where Robert Knight may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Robert Knight, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2023 | 2 | |
| 3 | 2023 | 2 | |
| 4 | 2021 | 21 | |
| 5 | 2020 | 4 | |
| 6 | 2016 | 22 | |
| 7 | 2009 | 44 | |
| 8 | 2009 | 42 | |
| 9 | 2009 | 82 | |
| 10 | 2008 | 135 | |
| 11 | 2008 | 117 | |
| 12 | 2008 | 19 | |
| 13 | 2006 | 116 | |
| 14 | Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletionbreakdown → | 2006 | 893 |
| 15 | An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma. | 2003 | 7 |
| 16 | 2000 | 28 | |
| 17 | 1998 | 126 | |
| 18 | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myelomabreakdown → | 1996 | 780 |
| 19 | Metabolic events that promote the terminal maturation of hematopoietic progenitor cells | 1992 | 2 |
| 20 | Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. | 1992 | 20 |
About Robert Knight
Robert Knight is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Acoustics and Ultrasonics, having authored 204 papers that have together received 12.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (109 papers), Cancer Treatment and Pharmacology (51 papers), Protein Degradation and Inhibitors (45 papers), Acute Myeloid Leukemia Research (37 papers), Chronic Lymphocytic Leukemia Research (22 papers), Developmental Biology and Gene Regulation (16 papers), Cancer therapeutics and mechanisms (14 papers) and Bone health and treatments (13 papers). The work is most often cited by research in Hematology (7.9k citations), Oncology (6.5k citations), Genetics (1.9k citations), Orthopedics and Sports Medicine (793 citations) and Molecular Biology (6.2k citations). Robert Knight has collaborated with scholars based in United States, United Kingdom and Greece. Frequent co-authors include Jerome B. Zeldis, Zhinuan Yu, Marta Olesnyckyj, Meletios Α. Dimopoulos, John J. Seaman, Dirk J. Reitsma, Joseph F. Simeone, John Patin, Allan Lipton and Alan F. List. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia Research, New England Journal of Medicine and Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.